

Applicability of trials in rheumatoid arthritis and osteoarthritis: A systematic review and meta-analysis of trial populations showing adequate proportion of women, but underrepresentation of elderly people

Andriko Palmowski, Thomas Buttgereit, Yannick Palmowski, Sabrina M. Nielsen, Maarten Boers, Robin Christensen, Frank Buttgereit

Document type

Postprint (accepted version)

This version is available at

<https://doi.org/10.17169/refubium-26668>

Citation details

Palmowski A, Buttgereit T, Palmowski Y, Nielsen SM, Boers M, Christensen R, et al. Applicability of trials in rheumatoid arthritis and osteoarthritis: A systematic review and meta-analysis of trial populations showing adequate proportion of women, but underrepresentation of elderly people. *Seminars in Arthritis and Rheumatism*. [Online] Elsevier BV; 2019;48(6): 983–989.
DOI: 10.1016/j.semarthrit.2018.10.017

Terms of use

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International license: <https://creativecommons.org/licenses/by-nc-nd/4.0/>

Applicability of trials in rheumatoid arthritis and osteoarthritis:

A systematic review and meta-analysis of trial populations showing adequate proportion of women, but underrepresentation of elderly people

Andriko Palmowski,^a Thomas Buttgereit,^{a, b} Yannick Palmowski,^c Sabrina M Nielsen,^{d, e} Maarten Boers,^f Robin Christensen,^{d, e} Frank Buttgereit^a

Affiliations

^a Department of Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, 10117 Berlin, Germany ^b Department of Dermatology, Venerology, and Allergology, Charité – University Medicine Berlin, 10117 Berlin, Germany ^c Center for Musculoskeletal Surgery, Charité – University Medicine Berlin, 10117 Berlin, Germany ^d Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, 2000 Frederiksberg, Denmark ^e Department of Rheumatology, Odense University Hospital, 5000 Odense, Denmark ^f Department of Epidemiology and Biostatistics, and Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Vrije Universiteit Amsterdam, 1007 MB Amsterdam, The Netherlands

Corresponding author

Andriko Palmowski, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany, Tel.: +49 176 551188 37, E-Mail: andriko.palmowski@charite.de

ABSTRACT

Objectives To evaluate whether elderly people and women are adequately represented in randomized controlled trials (RCT) in rheumatoid arthritis (RA) and osteoarthritis (OA).

Methods Four systematic searches in MEDLINE yielded RCT in RA and OA on any intervention published in 2016 and 2017 and population-based studies (PBS) in RA and OA published between 2013 and 2017. Random effects meta-analyses estimated the pooled proportion of elderly people (defined as being ≥ 65 years old), the mean age, its standard deviation (SD), and the proportion of women stratified by disease (RA and OA) and study type (RCT and PBS). Stratified estimates were subsequently compared.

Results 265 RCT comprising 51,240 participants and 53 PBS comprising 523,630 participants were included. In both RA and OA, RCT included lower proportions of elderly people than PBS: RA -0.18 (95% confidence interval -0.22 to -0.13); OA -0.20 (-0.30 to -0.09); had lower mean ages: RA -5.2 years (-6.8 to -3.5); OA -4.7 years (-7.5 to -2.0); and smaller SD: RA -1.9 years (-2.6 to -1.3); OA -2.7 years (-4.2 to -1.2); (all comparisons: $p \leq 0.001$). Proportions of women were comparable in RCT compared to PBS in both RA and OA.

Conclusions While women are adequately represented in RA and OA trials, the elderly are underrepresented, probably limiting applicability of current evidence to this growing subgroup. It is urgent to improve the inclusion of elderly people in clinical trials and study age as a determinant for outcome.

Systematic Review Registration PROSPERO (CRD42018085409)

Keywords Applicability, Generalizability, Elderly, Women, Rheumatoid Arthritis, Osteoarthritis

INTRODUCTION

Randomized controlled trials (RCT) shape the evidence base and are generally considered the gold standard in clinical research. However, their results are not necessarily applicable to the whole population suffering from the diseases under investigation.[1] Applicability (sometimes called generalizability or external validity) can be defined the extent to which ‘available research evidence can be directly utilized to answer the healthcare questions at hand’.[1, 2] It is a key factor in the translation of clinical research to the real world.[1] There are several characteristics in which trial populations may differ from real-world patients and which therefore affect trial result applicability, e.g., sex, age, and comorbidities.[1]

Despite the considerable rise in numbers of elderly people – ‘elderly’ commonly defined as aged 65 years or more – in countries all over the world,[3] this group is underrepresented in clinical trials across various medical fields.[4-11] Such underrepresentation bears considerable risks as elderly differ from younger people in several aspects, including pharmacodynamics and pharmacokinetics, comorbidity, polypharmacy, and physical performance.[12, 13] All of these may affect the potential for benefit and usually increase the risk of harm. Women are underrepresented, too, with similar implications.[1, 7, 14-16]

Empirical evidence on the representation of elderly people and women in rheumatologic clinical trials is lacking. Rheumatoid arthritis (RA) and osteoarthritis (OA) are two of the most common chronic rheumatic diseases and major contributors to global disability.[17-22] Both tend to occur predominantly in elderly people – and mostly in women.[17-23] We therefore investigated whether RCT reflect these tendencies, possess similar characteristics in age distribution measures and include proportions of elderly people and women comparable to real-world data obtained by population-based studies (PBS) including registries. Additionally, we assessed whether there are associations between proportions of elderly people and industry funding and different types of intervention.

METHODS

This study is part of the GLORIA project and trial (Glucocorticoid low-dose outcome in rheumatoid arthritis study; <http://www.gloriatrial.org/>; registered on <http://clinicaltrials.gov/>; identifier NCT02585258).[24] It conforms to the *PRISMA* (for systematic reviews of interventional studies) and *MOOSE* (for systematic reviews of observational studies) guidelines (see supplementary file for research checklists).[25, 26] The prespecified protocol (see supplementary file) was preregistered with the protocol registry for systematic reviews, PROSPERO (CRD42018085409).

Abbreviations

RCT – Randomized controlled trial; RA – Rheumatoid arthritis; OA – Osteoarthritis; PBS – Population-based study; SD – Standard deviation

Search strategy

Using the biomedical database MEDLINE (via PubMed), we conducted separate searches for RCT and PBS in RA and OA through 31 December 2017. We limited the search for RCT to trials published from 1 January 2016, whereas our search for PBS began with 1 January 2013 to ensure sufficient real-world data. Additionally, we performed a hand search for relevant publications including a scan of the references of major guidelines and reviews of RA and OA. We decided *a priori* that we would not attempt to contact study authors or include unpublished studies. For exact search strings, which we developed with researchers experienced in systematic reviews and meta-analyses, please consider our study protocol.

Eligibility criteria

All studies (both RCT and PBS) had to report the mean or median age at baseline of all included patients/populations. Corresponding to GLORIA collaborators, we excluded publications in languages other than English, French, Spanish, German, Italian, Hungarian, Portuguese, Dutch, Slovakian, and Romanian. We defined PBS as observational studies fulfilling one of the following criteria: study objective being the determination of RA or OA prevalence in the general population; studies with other objectives, but undertaken in prevalent RA or OA populations without apparent selection mechanisms as to age or gender; or studies in ongoing RA or OA registries.[27] For additional specifications please refer to our study protocol.

Two reviewers (AP and TB) independently selected the studies. After removing duplicates, they screened the articles by title and abstract, and assessed potentially eligible articles in full-text. They achieved consensus by discussion when necessary.

Data extraction

We extracted the data using predefined data extraction sheets which we derived from the Cochrane Collaboration's recommendations for data extraction and modified for our purposes.[28] We dichotomized information on funding into *any industry funding* and *no industry funding*, and categorized treatment modalities into *pharmacological*, *surgical*, *physical/physiotherapeutic*, and *psychological*.

Risk of bias

Two reviewers (AP and TB) independently assessed risk of bias of the included PBS using the newest version of the *Joanna Briggs Institute Critical Appraisal Checklist for Prevalence Studies*. [29, 30] Discussion resolved rating discrepancies. Regarding RCT, our sole outcomes were baseline

characteristics, so we considered quality appraisal not to be necessary. We did not assess risk of bias across studies, e.g., publication bias,[25] since, in our opinion, there is no reason to believe that any of our study variables makes studies more or less likely to get published.

Data synthesis

We used R (R Foundation for Statistical Computing, Vienna, Austria) with packages *meta* and *metafor* and Microsoft Excel 2016 (Microsoft Corporation, Redmond, WA, USA) software for data extraction, management, and analysis. The format of reporting results conforms to guidelines recently proposed by one of us.[31]

We either extracted the proportion of elderly participants from the research manuscript or estimated it. In the latter case, we estimated the proportion utilizing an established method under assumption that age is distributed normally, but with truncation as trials employ upper and/or lower age limits as exclusion criteria.[8, 9, 32] The model considers studies to be either singly (assuming a lower age limit of 18 years if not reported otherwise) or doubly truncated.

We conducted restricted maximum likelihood random effects meta-analyses on each of our four outcomes: the proportion of elderly people (i.e., aged ≥ 65 years), the mean age, its SD (as a measure of dispersion), and the proportion of women (all performed separately for RCT and PBS and stratified by disease). We subsequently compared the results and tested the differences for statistical significance with two-sample Z-tests.[33] We evaluated heterogeneity with Cochran's Q-statistic and present it as an I^2 -value, which estimates the total percentage of variance across studies due to heterogeneity rather than statistical error.[28, 34] In RCT, we additionally assessed whether representation of elderly people differed across funding and intervention types through meta-regression analysis including a factor for funding or intervention and testing for moderators with Wald-type tests.[35] We set the two-sided significance level α at .05. For additional specifications concerning data synthesis please refer to our study protocol.

RESULTS

Search results

Our database search yielded 3,065 results (**Figure 1**). We identified 11 additional articles by hand search. Of these 3,076 publications, 265 RCT and 53 PBS were finally deemed eligible (see supplementary file for a list of all included studies).

Study characteristics

RCT included 51,240 patients (30,410 RA and 20,830 OA patients; **Table 1**). The majority of included RCT originated from Europe and Asia, although most RA RCT were not limited to one region. In RA RCT, industry funding was more prominent than in OA RCT. None of the studies that explicitly excluded elderly patients provided a reason for doing so. Seven RCT (3%) reported the proportion of elderly participants, and five RCT (2%), all on OA, assessed the influence of participant age on outcomes.

PBS included 523,630 patients (449,329 RA patients and 74,301 OA patients). Just like RCT, most PBS were conducted in Europe and Asia. No PBS reported the proportion of elderly participants.

Risk of bias assessments are presented in the supplementary file. In 38% of PBS, authors did not report the number of people willing or refusing to participate, and in 34% it was unclear whether data analysis was performed with sufficient coverage of the identified sample. Other potential sources of bias include ambiguity regarding disease identification methods (30%) and execution of these (21%). The sample size was considered low in 25% of PBS. Overall, studies in healthcare and insurance databases had the lowest percentage of questions answered “no” (0% of questions).

Comparison of RCT and PBS

In both RA and OA, RCT included significantly fewer elderly people than did PBS (**Figure 2**): RA -0.18 (95% confidence interval -0.22 to -0.13); OA -0.20 (-0.30 to -0.09); and had significantly lower mean ages: RA -5.2 years (-6.8 to -3.5); OA -4.7 years (-7.5 to -2.0). RCT also had smaller SD: RA -1.9 years (-2.6 to -1.3); OA -2.7 years (-4.2 to -1.2); (all comparisons $p \leq 0.001$). In both RA and OA, RCT included similar proportions of women compared to PBS: RA 0.02 (-0.01 to 0.05); OA -0.04 (-0.10 to 0.03). Heterogeneity was considerable in all meta-analyses with I^2 values between 96% and 100%. Individual meta-analyses are presented in the supplementary file.

Stratified analyses

Funding source did not influence the deficit of elderly in RCT (RA, $p = 0.82$; OA, $p = 0.26$; **Table 2**). Type of intervention did influence the deficit, but only in RA (RA, $p = 0.02$; OA, $p = 0.60$).

DISCUSSION

We found the elderly to be underrepresented in RA and OA trials; mean ages and the variation in age (SD) were lower in RCT than in PBS. RCT included proportions of women comparable to real-world

settings. While the proportion of included elderly patients showed no association with industry funding, it differed in RA RCT but not in OA RCT depending on the intervention.

Intense and successful research in rheumatology has led to crucial discoveries in disease mechanisms and both diagnostic and therapeutic management over the last two decades. While all this research surely has and will continue to benefit most patients, our study suggests applicability to the large subgroup of elderly patients may be limited.

Underrepresentation of the elderly in medical science is not a new phenomenon.[10] Since its documentation in cardiology in the 1990s,[7] it has been confirmed in renal, neurological, and oncological diseases, in diabetes, and in surgical procedures (see supplementary file for a list of studies on this subject). Current guidelines still widely rely on trials lacking applicability to elderly patients.[11, 16]

Various national and international institutions have acknowledged this problem and have undertaken efforts to tackle this issue. The U.S. food and drug administration (FDA) requires drug sponsors to report trial data by age,[36, 37] but low numbers of elderly in clinical trials diminish the statistical power to detect significant differences between them and their younger counterparts in both efficacy and safety.[37, 38] The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use and the European Forum for Good Clinical Practice have issued guidance for research in the geriatric population.[38, 39] It has been demanded repeatedly that institutional review boards and journals pay attention to whether applicability of trial results concerning age is assured.[7, 40] All the same, elderly people still seem to be underrepresented in clinical trials.

In RA and OA trials, two publications suggested underrepresentation of the elderly: In RA, patients in RCT of etanercept, rituximab, and tocilizumab were younger than those enrolled in observational studies on these agents.[41] In OA, 38% of trials published before 2007 did not have patients above the age of 80 years, and 11% explicitly excluded elderly patients.[42] In our study this proportion was more pronounced at 36%.

It remains unclear why the elderly are actively excluded by trials installing upper age limits. No trial in our study justified doing so, although justification of exclusion criteria has been demanded repeatedly.[5] In trials, investigators generally aim for homogeneous study samples and might fear higher rates of (serious) adverse events and drop-outs in aged people.[4, 43, 44] Other mechanisms

that keep the elderly from participating are exclusion criteria related to age such as comorbidities, strict organ function criteria, or performance status.[45, 46] Physician- and patient-level factors that add to this are, amongst others, physicians being reluctant to include elderly people due to fear of increased toxicity, and elderly people themselves having difficulties judging benefits and risks.[45-47]

We did not find a statistically significant association between industry funding and the proportion of elderly people. Previous studies have come to varying results, with industry funding being associated with higher (in heart failure trials), lower (across trials of all specialties), and no different rates (in trials on statins, non-steroidal anti-inflammatory drugs, and type 2 diabetes mellitus) of explicit exclusion of elderly people.[4, 5, 48, 49] The lack of influence of type of intervention in OA trials (in contrast to RA trials) is surprising, since adequate interventions (e.g., endoprosthetic surgery) depend on the severity of the disease (e.g., late-stage OA) and could therefore be associated with age. To sum up, evidence is ambiguous, but associations in both respects might vary between diseases.

Numerous attempts have been made to analyze how age affects trial outcomes, and studies doing so have yielded quite heterogeneous results. As one example, thrombolytic and interventional therapy is associated with higher mortality in older patients with myocardial infarction, while the elderly had similar response and survival rates in trials on lung and breast cancer.[50-53] Recent research suggests lower response rates to biologicals in elderly RA patients and a diminished benefit-to-risk ratio.[54-56] Of all 265 RCT included in our study, only five analyzed age as a determinant for outcome. Their results were conflicting: In two studies, older participants profited less or had worse outcomes than younger ones,[57, 58] but experienced a more pronounced treatment effect in another.[59]

In contrast to the past and the present in other medical specialties,[7, 14-16] we did not find women to be underrepresented. In fact, women make up the majority of patients included in current RA and OA clinical trials. Generally, this is consistent with the distribution of RA and OA in men and women. With increasing age, however, gender disparities in both diseases decrease.[60, 61] Thus, it should be underlined that current evidence is especially sparse regarding elderly men.

Both efficacy and safety data must be interpreted with caution if they stem from study populations which differ from general diseased populations in age or sex (or disease duration, or disease severity, etc.). In the past, young Caucasian males were usually considered the ideal study subjects, and pharmacodynamic and -kinetic differences in other subpopulations were paid little attention, as was the case with differing comorbidities or drug interactions (think of polypharmacy in the elderly).[10] Drugs were approved without sufficient study in elderly people, non-whites, or women.[10]

An infamous example of this phenomenon is benoxaprofen, a drug introduced in the 1980s to treat arthritic conditions.[62] Benoxaprofen had previously been studied in large clinical trials. However, its licenses were suspended only two years after launch because of unacceptable rates of (serious) adverse events in ‘real-world’ patients, including deaths – mostly in the elderly, who had been studied very little before.[62] Researchers later found tremendous pharmacological differences between the elderly and younger (or – as the researchers put it – ‘*normal*’) patients.[63]

Researchers should investigate the effect of age and other covariates such as sex on outcomes routinely on trial-level data. However, this is only useful when adequate numbers of, e.g., elderly people are included in clinical trials.[37, 38] The current meta-analysis was performed under the umbrella of the GLORIA project, which also includes a trial focusing specifically on RA patients aged 65 or over.[24] While studies aimed at younger populations might measure outcomes and define endpoints that are less relevant to elderly people, performing trials focused on the elderly is an option. This option takes into consideration that some outcomes are particularly valuable for older patients.[64-66] Such relevant outcomes include functional ones (e.g., quality of life) instead of solely disease-specific ones.[64-66] Factors that impede inclusion and retention of the elderly (at trial-, physician- and patient-level) have been identified and should be countered.[45-47, 67-70] Another option is to replace the traditional explanatory RCT by a pragmatic design: for example, the GLORIA trial has very ‘relaxed’ eligibility criteria, uses routinely collected data where possible, and takes place in the routine clinical setting.[71] Yet another option is to construct and conduct RCT on the foundation of ongoing observational studies. These so-called registry-based RCT usually cover real-world settings and go with higher applicability as well.[72]

To our knowledge, this is the first study to prove and quantify underrepresentation of elderly people in rheumatology by comparing RCT and PBS. Strengths include the high number of studies and participants, a systematic literature search not limited to the English language, and protocolized execution. Study selection and risk of bias assessment were performed independently by two authors to reduce the risk of systematic bias. We excluded RCT that only presented baseline characteristics from study finishers, so our results should not be affected by the possibility that older patients may be prone to dropping out.

This study also has limitations. We have restricted our search to MEDLINE, but it is unlikely that our results would differ by including trials indexed elsewhere only. Furthermore, with our search restricted to RCT published within the last two years, our analyses reflect only the current situation, but we feel

that is most relevant. Finally, the assessment of the 'real' prevalence is dependent on the quality of population-based evidence, and some studies had flaws. Nonetheless, we are convinced these flaws do not cast doubt on our overall results.

We did encounter considerable heterogeneity in all meta-analyses. Some heterogeneity will be due to our 'relaxed' eligibility criteria, which led to inclusion of a variety of study types and interventions. In RCT, heterogeneity may be caused by studies being aimed at or explicitly excluding elderly people, women, or patients in a certain disease stage. Regarding both RCT and PBS, heterogeneity could also be explained by varying demographics across different regions. Overall, though, only three RA PBS and one OA PBS included proportions of elderly people that were smaller than pooled RCT estimates. Accordingly – since meta-analytical estimates were consistent – we did not perform additional sensitivity analyses.[34] Finally, we had to estimate proportions of elderly people in the majority of RCT and PBS. However, our method to do so is established and has been applied repeatedly.[8, 9]

CONCLUSIONS

Our study proves that elderly people, but not women, are significantly underrepresented in randomized clinical trials on rheumatoid arthritis and osteoarthritis, raising serious concerns about applicability of their results. It is urgent to improve the inclusion of elderly people in clinical trials and to study age and sex as a determinant for outcome.

FOOTNOTES

Contributors

AP, YP, and FB had the idea for the study. AP, YP, MB, RC, and FB developed the study design. AP and TB performed the study selection and risk of bias assessment. AP extracted the data. AP, SMN, RC, and FB analyzed and interpreted the data. All authors critically revised the manuscript and approved the final version for submission. FB is the guarantor, had full access to all the data, takes responsibility for the integrity of the data and the accuracy of the data analysis, and had final responsibility for the decision to submit this article for publication. All authors have read, and confirm that they meet, ICMJE criteria for authorship.

Acknowledgements

The authors wish to thank Dörte Huscher for her helpful assistance concerning statistical issues.

Funding

This study is part of the GLORIA trial and project (Glucocorticoid low-dose outcome in rheumatoid arthritis study; <http://www.gloriatrial.org/>; registered on <http://clinicaltrials.gov/>; identifier NCT02585258) and has received funding from the European Union's Horizon 2020 Framework Programme for Research and Innovation under grant agreement no. 634886. Musculoskeletal Statistics Unit, The Parker Institute, (SMN and RC) is supported by grants from The Oak Foundation. The Oak Foundation is a group of philanthropic organizations that, since its establishment in 1983, has given grants to not-for-profit organizations around the world. Funders had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Competing Interests

AP, TB, MB, and FB have received grants from the European Union (Horizon 2020 Framework Programme for Research and Innovation) during the conduct of the study. YP and SMN have nothing to disclose. RC reports non-financial support from board membership, grants from consultancy (AbbVie, Amgen, Axellus A/S, Biogen, Bristol-Myers Squibb, Cambridge Weight Plan, Celgene, Eli Lilly, Hospira, MSD, Norpharma, Novartis, Orkla Health, Pfizer, Roche, Sobi, Takeda), personal fees from employment (Research Unit for Musculoskeletal Function and Physiotherapy, Institute of Sports Science and Clinical Biomechanics, University of Southern Denmark), non-financial support from expert testimony, grants/grants pending (Axellus A/S, AbbVie, Cambridge Weight Plan, Janssen, MSD, Mundipharma, Novartis, and Roche), payment for lectures including service on speakers bureaus (Abbott, Amgen, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb,

Cambridge Weight Plan, Ipsen, Janssen, Laboratoires Expanscience, MSD, Mundipharma, Norpharma, Novartis, Pfizer, Roche, Rottapharm-Madaus, Sobi, and Wyeth), payment for manuscript preparation (Axellus, Bristol-Myers Squibb, and Cambridge Weight Plan, Aleris-Hamlet (via Norpharma)), non-financial support from patents (planned, pending or issued), non-financial support from royalties, payment for development of educational presentations (Bristol-Myers Squibb, MSD, Pfizer), non-financial support from stock/stock options, grants from travel/accommodations/meeting expenses unrelated to activities listed (Abbott, AbbVie, Axellus, Biogen, Bristol-Myers Squibb, Cambridge Weight Plan, Celgene, Laboratoires Expanscience, Norpharma, Novartis, Pfizer, Roche, Rottapharm-Madaus, and Wyeth), non-financial support from others (err on the side of full disclosure) outside the submitted work; RC is involved in many health-care initiatives and research that could benefit from wide uptake of this publication (including Cochrane, OMERACT, IDEOM, RADS, and the GRADE Working Group). Musculoskeletal Statistics Unit, The Parker Institute is grateful for the financial support received from public and private foundations, companies and private individuals over the years.

Ethics Approval

Not required.

Data Sharing

FB is willing to examine all requests for the full dataset during a period of 5 years from the date of this publication. The GLORIA steering committee will be involved in case of query about access.

Transparency

The guarantor (FB) affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned and registered have been explained.

REFERENCES

- [1] Rothwell PM. External validity of randomised controlled trials: "To whom do the results of this trial apply?". *Lancet* 2005;365(9453):82-93. doi: 10.1016/S0140-6736(04)17670-8.
- [2] Schünemann HJ, Tugwell P, Reeves BC, et al. Non-randomized studies as a source of complementary, sequential or replacement evidence for randomized controlled trials in systematic reviews on the effects of interventions. *Research Synthesis Methods* 2013;4(1):49-62. doi: 10.1002/jrsm.1078.
- [3] World Health Organization. World Report on Ageing and Health. 2015. <http://www.who.int/ageing/events/world-report-2015-launch/en/> (accessed June 2018).
- [4] Cruz-Jentoft AJ, Carpena-Ruiz M, Montero-Erasquin B, et al. Exclusion of older adults from ongoing clinical trials about type 2 diabetes mellitus. *J Am Geriatr Soc* 2013;61(5):734-8. doi: 10.1111/jgs.12215.
- [5] Cherubini A, Oristrell J, Pla X, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. *Arch Intern Med* 2011;171(6):550-6. doi: 10.1001/archinternmed.2011.31.
- [6] Schiphorst AH, Pronk A, Borel Rinkes IH, et al. Representation of the elderly in trials of laparoscopic surgery for colorectal cancer. *Colorectal Dis* 2014;16(12):976-83. doi: 10.1111/codi.12806.
- [7] Gurwitz JH, Col NF, Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. *JAMA* 1992;268(11):1417-22.
- [8] Konrat C, Boutron I, Trinquart L, et al. Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. *PLoS ONE* 2012;7(3):e33559. doi: 10.1371/journal.pone.0033559.
- [9] Bourgeois FT, Orenstein L, Ballakur S, et al. Exclusion of Elderly People from Randomized Clinical Trials of Drugs for Ischemic Heart Disease. *J Am Geriatr Soc* 2017 doi: 10.1111/jgs.14833.
- [10] Cotton P. Is there still too much extrapolation from data on middle-aged white men? *JAMA* 1990;263(8):1049-50. doi: 10.1001/jama.1990.03440080013002.
- [11] O'Hare AM, Kaufman JS, Covinsky KE, et al. Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults? *Ann Intern Med* 2009;150(10):717-24.
- [12] Sera LC, McPherson ML. Pharmacokinetics and pharmacodynamic changes associated with aging and implications for drug therapy. *Clin Geriatr Med* 2012;28(2):273-86. doi: 10.1016/j.cger.2012.01.007.
- [13] Budnitz DS, Lovegrove MC, Shehab N, et al. Emergency hospitalizations for adverse drug events in older Americans. *N Engl J Med* 2011;365(21):2002-12. doi: 10.1056/NEJMsa1103053.
- [14] Lee PY, Alexander KP, Hammill BG, et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. *JAMA* 2001;286(6):708-13.
- [15] Liu KA, Mager NA. Women's involvement in clinical trials: historical perspective and future implications. *Pharm Pract (Granada)* 2016;14(1):708. doi: 10.18549/PharmPract.2016.01.708.
- [16] Sardar M, Badri M, Prince CT, et al. Underrepresentation of women, elderly patients, and racial minorities in the randomized trials used for cardiovascular guidelines. *JAMA Intern Med* 2014;174(11):1868-70. doi: 10.1001/jamainternmed.2014.4758.
- [17] Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. *Ann Rheum Dis* 2014;73(7):1316-22. doi: 10.1136/annrheumdis-2013-204627.
- [18] Cross M, Smith E, Hoy D, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. *Ann Rheum Dis* 2014;73(7):1323-30. doi: 10.1136/annrheumdis-2013-204763.
- [19] Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. *Arthritis Rheum* 2008;58(1):15-25. doi: 10.1002/art.23177.

- [20] Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. *Arthritis Rheum* 2008;58(1):26-35. doi: 10.1002/art.23176.
- [21] Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. *Bull World Health Organ* 2003;81(9):646-56.
- [22] Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. *Arthritis Rheum* 2011;63(3):633-9. doi: 10.1002/art.30155.
- [23] Rasch EK, Hirsch R, Paulose-Ram R, et al. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: Effect of different methods of case classification. *Arthritis & Rheumatism* 2003;48(4):917-26. doi: doi:10.1002/art.10897.
- [24] Hartman L, Rasch LA, Klausch T, et al. Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial. *Trials* 2018;19(1):67. doi: 10.1186/s13063-017-2396-3.
- [25] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med* 2009;151(4):264-9, w64.
- [26] Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. *JAMA* 2000;283(15):2008-12. doi: 10.1001/jama.283.15.2008.
- [27] Lieb R. Population-Based Study. In: Gellman MD, Turner JR, eds. *Encyclopedia of Behavioral Medicine*. New York, NY: Springer New York 2013:1507-08.
- [28] Higgins J, Green S. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1*. London, United Kingdom: Cochrane Collaboration 2011.
- [29] Munn Z, Moola S, Riitano D, et al. The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. *Int J Health Policy Manag* 2014;3(3):123-8. doi: 10.15171/ijhpm.2014.71.
- [30] Joanna Briggs Institute. The Joanna Briggs Institute Critical Appraisal tools for use in JBI Systematic Reviews - Checklist for Prevalence Studies. 2017. http://joannabriggs.org/assets/docs/critical-appraisal-tools/JBI_Critical_Appraisal-Checklist_for_Prevalence_Studies2017.pdf (accessed January 2018).
- [31] Boers M. Graphics and statistics for cardiology: designing effective tables for presentation and publication. *Heart* 2018;104(3):192-200. doi: 10.1136/heartjnl-2017-311581.
- [32] Cohen AC. Estimating the Mean and Variance of Normal Populations from Singly Truncated and Doubly Truncated Samples. *Ann Math Statist* 1950;21(4):557-69. doi: 10.1214/aoms/1177729751.
- [33] Altman DG, Bland JM. Interaction revisited: the difference between two estimates. *BMJ* 2003;326(7382):219. doi: 10.1136/bmj.326.7382.219.
- [34] Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327(7414):557-60. doi: 10.1136/bmj.327.7414.557.
- [35] Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. *2010* 2010;36(3):48. doi: 10.18637/jss.v036.i03.
- [36] Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. *J Clin Oncol* 2004;22(22):4626-31. doi: 10.1200/jco.2004.02.175.
- [37] Crosse M. Prescription Drugs: FDA Guidance and Regulations Related to Data on Elderly Persons in Clinical Drug Trials. Washington DC: United States Government Accountability Office, 2007.
- [38] International Conference on Harmonisation. Studies in Support of Special Populations: Geriatrics, current Step 4 Version. 1993. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E7/Step4/E7_Guideline.pdf (accessed June 2018).
- [39] European Commission. Medical Research for and with Older People in Europe. 2013. https://ec.europa.eu/eip/ageing/library/medical-research-and-older-people-europe_en (accessed June 2018).

- [40] Bayer A, Tadd W. Unjustified exclusion of elderly people from studies submitted to research ethics committee for approval: descriptive study. *BMJ* 2000;321(7267):992-3. doi: 10.1136/bmj.321.7267.992.
- [41] Kilcher G, Hummel N, Didden EM, et al. Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries. *Rheumatology (Oxford)* 2017;kex394-kex94. doi: 10.1093/rheumatology/kex394.
- [42] Liberopoulos G, Trikalinos NA, Ioannidis JP. The elderly were under-represented in osteoarthritis clinical trials. *J Clin Epidemiol* 2009;62(11):1218-23. doi: 10.1016/j.jclinepi.2008.12.009.
- [43] Chatfield MD, Brayne CE, Matthews FE. A systematic literature review of attrition between waves in longitudinal studies in the elderly shows a consistent pattern of dropout between differing studies. *J Clin Epidemiol* 2005;58(1):13-9. doi: 10.1016/j.jclinepi.2004.05.006.
- [44] Warner ET, Glasgow RE, Emmons KM, et al. Recruitment and retention of participants in a pragmatic randomized intervention trial at three community health clinics: results and lessons learned. *BMC Public Health* 2013;13:192. doi: 10.1186/1471-2458-13-192.
- [45] Denson AC, Mahipal A. Participation of the elderly population in clinical trials: barriers and solutions. *Cancer Control* 2014;21(3):209-14. doi: 10.1177/107327481402100305.
- [46] Carroll CB, Zajicek JP. Designing clinical trials in older people. *Maturitas* 2011;68(4):337-41. doi: 10.1016/j.maturitas.2011.02.002.
- [47] Basche M, Baron AE, Eckhardt SG, et al. Barriers to enrollment of elderly adults in early-phase cancer clinical trials. *J Oncol Pract* 2008;4(4):162-8. doi: 10.1200/jop.0842001.
- [48] Van Spall HC, Toren A, Kiss A, et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: A systematic sampling review. *JAMA* 2007;297(11):1233-40. doi: 10.1001/jama.297.11.1233.
- [49] Bartlett C, Doyal L, Ebrahim S, et al. The causes and effects of socio-demographic exclusions from clinical trials. *Health Technol Assess* 2005;9(38):iii-iv, ix-x, 1-152.
- [50] Thiemann DR, Coresh J, Schulman SP, et al. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. *Circulation* 2000;101(19):2239-46.
- [51] Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. *N Engl J Med* 1999;341(9):625-34. doi: 10.1056/nejm199908263410901.
- [52] Christman K, Muss HB, Case LD, et al. Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience. *JAMA* 1992;268(1):57-62.
- [53] Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med* 2005;353(2):123-32. doi: 10.1056/NEJMoa050753.
- [54] Daien CI, Morel J. Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine. *Mediators Inflamm* 2014;2014:386148. doi: 10.1155/2014/386148.
- [55] Yamanaka H, Tanaka Y, Inoue E, et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). *Mod Rheumatol* 2011;21(2):122-33. doi: 10.1007/s10165-010-0366-7.
- [56] Dalal DS, Duran J, Brar T, et al. Efficacy and Safety of Biological Agents in the Older Rheumatoid Arthritis patients compared to Young: A Systematic Review and Meta-analysis. *Semin Arthritis Rheum* 2018 doi: 10.1016/j.semarthrit.2018.07.009.
- [57] Ibrahim SA, Blum M, Lee GC, et al. Effect of a Decision Aid on Access to Total Knee Replacement for Black Patients With Osteoarthritis of the Knee: A Randomized Clinical Trial. *JAMA Surg* 2017;152(1):e164225. doi: 10.1001/jamasurg.2016.4225.
- [58] Lampe F, Fiedler F, Marques CJ, et al. Surgically modifiable factors measured by computer-navigation together with patient-specific factors predict knee society score after total knee arthroplasty. *BMC Musculoskelet Disord* 2016;17:78. doi: 10.1186/s12891-016-0929-7.
- [59] Broderick JE, Keefe FJ, Schneider S, et al. Cognitive behavioral therapy for chronic pain is effective, but for whom? *Pain* 2016;157(9):2115-23. doi: 10.1097/j.pain.0000000000000626.

- [60] Oliver JE, Silman AJ. Why are women predisposed to autoimmune rheumatic diseases? *Arthritis Res Ther* 2009;11(5):252. doi: 10.1186/ar2825.
- [61] Verbrugge LM. Women, men, and osteoarthritis. *Arthritis Care Res* 1995;8(4):212-20.
- [62] Benoxaprofen. *Br Med J (Clin Res Ed)* 1982;285(6340):459-60.
- [63] Kamal A, Koch IM. Pharmacokinetic studies of benoxaprofen in geriatric patients. *Eur J Rheumatol Inflamm* 1982;5(2):76-81.
- [64] Ferrucci L, Guralnik JM, Studenski S, et al. Designing randomized, controlled trials aimed at preventing or delaying functional decline and disability in frail, older persons: a consensus report. *J Am Geriatr Soc* 2004;52(4):625-34. doi: 10.1111/j.1532-5415.2004.52174.x.
- [65] Allore HG, Tinetti ME, Gill TM, et al. Experimental designs for multicomponent interventions among persons with multifactorial geriatric syndromes. *Clin Trials* 2005;2(1):13-21. doi: 10.1191/1740774505cn067oa.
- [66] Working Group on Functional Outcome Measures for Clinical Trials. Functional outcomes for clinical trials in frail older persons: time to be moving. *J Gerontol A Biol Sci Med Sci* 2008;63(2):160-4.
- [67] Siu LL. Clinical Trials in the Elderly — A Concept Comes of Age. *N Engl J Med* 2007;356(15):1575-76. doi: 10.1056/NEJMe078023.
- [68] Provencher V, Mortenson WB, Tanguay-Garneau L, et al. Challenges and strategies pertaining to recruitment and retention of frail elderly in research studies: a systematic review. *Arch Gerontol Geriatr* 2014;59(1):18-24. doi: 10.1016/j.archger.2014.03.006.
- [69] Hurria A, Dale W, Mooney M, et al. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. *J Clin Oncol* 2014;32(24):2587-94. doi: 10.1200/jco.2013.55.0418.
- [70] McMurdo ME, Roberts H, Parker S, et al. Improving recruitment of older people to research through good practice. *Age Ageing* 2011;40(6):659-65. doi: 10.1093/ageing/afr115.
- [71] Zuidegeest MGP, Goetz I, Groenwold RHH, et al. Series: Pragmatic trials and real world evidence: Paper 1. Introduction. *J Clin Epidemiol* 2017;88:7-13. doi: 10.1016/j.jclinepi.2016.12.023.
- [72] Lauer MS, D'Agostino RBS. The Randomized Registry Trial — The Next Disruptive Technology in Clinical Research? *N Engl J Med* 2013;369(17):1579-81. doi: 10.1056/NEJMp1310102.

TABLES

Table 1. Study characteristics.

	PBS (n = 53)		RCT (n = 265)	
	RA (n = 42)	OA (n = 11)	RA (n = 102)	OA (n = 163)
Location				
Europe	38	27	28	39
Asia	30	36	23	26
Multiple	5	9	41	1
North America	10	9	3	18
Oceania	2	0	1	10
Central and South America	12	18	3	4
Africa	2	0	1	3
Intervention				
Pharmacological			82	25
on biologic agents ^a			69	7
on biosimiliars ^b	NA	NA	16	0
Physical/physiotherapeutic			9	32
Surgical			0	22
Psychological			4	4
Other			5	18
Design^c				
Cross-sectional	41	73		
Cohort (including registries)	41	9	NA	NA
Healthcare and insurance databases	21	18		
Funding				
No industry funding	67	82	30	64
Any industry funding	26	18	67	24
Not available ^d	7	0	3	12
Upper age limit				
Not present			72	64
Present	NA	NA	28	36
Justification given			0	0
Sample size^e				
	1,107	696	212	81
	(409 - 8,998)	(161 - 11,111)	(72 - 386)	(48 - 164)

Numbers are percentages if not stated otherwise. PBS, population-based studies, RCT, randomized controlled trials, RA, rheumatoid arthritis, OA, osteoarthritis, and NA, not applicable. ^aPercentages are based on all pharmacological studies in the respective disease. ^bPercentages are based on all studies on biologic agents in the respective disease. ^cMultiple nominations per study possible. ^dE.g., no funding and conflicts of interest statement. ^eMedian (IQR).

Table 2. Proportions of elderly people in randomized controlled trials stratified by funding and intervention.

	RA		OA			
Funding						
No industry funding	0.13	0.17	0.20	0.42	0.47	0.52
Any industry funding	0.14	0.16	0.18	0.33	0.42	0.50
Intervention						
Psychological	0.19	0.29	0.39	0.29	0.50	0.72
Surgical		-		0.40	0.49	0.58
Physical/physiotherapeutic	0.11	0.18	0.25	0.39	0.46	0.54
Pharmacological	0.14	0.16	0.18	0.36	0.44	0.53
Other	0.00	0.09	0.18	0.29	0.39	0.49

Numbers are the proportion of elderly people surrounded by 95% confidence intervals. RA, rheumatoid arthritis, and OA, osteoarthritis.

FIGURES




Figure 1. Search flow of population-based studies (PBS) and randomized controlled trials (RCT) in rheumatoid arthritis (RA) and osteoarthritis (OA). Database searches were carried out on January 19, 2018.




Figure 2. Meta-analyses' estimates of population-based studies (PBS) and randomized controlled trials (RCT) in rheumatoid arthritis (RA) and osteoarthritis (OA) for the proportion of elderly people, mean age, standard deviation of age, and the proportion of women. CI, confidence interval.